Medifast Inc MED
We take great care to ensure that the data presented and summarized in this overview for MEDIFAST INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MED
View all-
Jim Simons Renaissance Technologies LLC | New York, Ny904KShares$13.3 Million0.03% of portfolio
-
Black Rock Inc. New York, NY829KShares$12.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA758KShares$11.2 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY353KShares$5.2 Million0.0% of portfolio
-
Hotchkis & Wiley Capital Management LLC Los Angeles, CA295KShares$4.34 Million0.02% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY289KShares$4.25 Million0.0% of portfolio
-
Morgan Stanley New York, NY286KShares$4.21 Million0.0% of portfolio
-
Federated Hermes, Inc. Pittsburgh, PA279KShares$4.12 Million0.01% of portfolio
-
Bank Of America Corp Charlotte, NC276KShares$4.07 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA273KShares$4.02 Million0.01% of portfolio
Latest Institutional Activity in MED
Top Purchases
Top Sells
About MED
Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. The company offers bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serves, shakes, smoothies, soft bakes, and soups under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands. It markets its products through point-of-sale transactions over ecommerce platform. The company was founded in 1980 and is headquartered in Baltimore, Maryland.
Insider Transactions at MED
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 13
2024
|
Jonathan Barrett Mac Kenzie VP, Finance & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
11
-0.28%
|
$198
$18.9 P/Share
|
|
Jun 20
2024
|
Andrea B Thomas Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,596
+33.92%
|
-
|
|
Jun 20
2024
|
Jeffrey J Brown Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,177
+29.23%
|
$133,947
$11.33 P/Share
|
|
Jun 20
2024
|
Scott Schlackman Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,596
+31.45%
|
-
|
|
Jun 20
2024
|
Michael A. Hoer Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,596
+30.58%
|
-
|
|
Jun 20
2024
|
Elizabeth A. Geary Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,596
+44.05%
|
-
|
|
Mar 15
2024
|
Daniel R Chard Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,409
-1.11%
|
$122,724
$36.61 P/Share
|
|
Mar 15
2024
|
Jonathan Barrett Mac Kenzie VP, Finance & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
134
-1.67%
|
$4,824
$36.61 P/Share
|
|
Mar 15
2024
|
James P. Maloney Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
616
-1.03%
|
$22,176
$36.61 P/Share
|
|
Mar 13
2024
|
Jonathan Barrett Mac Kenzie VP, Finance & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
2,565
+38.77%
|
-
|
|
Mar 13
2024
|
James P. Maloney Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,718
+30.2%
|
-
|
|
Mar 13
2024
|
Daniel R Chard Chairman & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
45,087
+30.4%
|
-
|
|
Mar 08
2024
|
Scott Schlackman Director |
SELL
Open market or private sale
|
Direct |
4,053
-18.55%
|
$158,067
$39.43 P/Share
|
|
Mar 08
2024
|
Scott Schlackman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,300
+9.9%
|
$35,100
$27.68 P/Share
|
|
Feb 14
2024
|
James P. Maloney Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
648
-5.36%
|
$33,696
$52.68 P/Share
|
|
Feb 14
2024
|
James P. Maloney Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,328
+16.16%
|
-
|
|
Feb 14
2024
|
Daniel R Chard Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,471
-8.6%
|
$284,492
$52.68 P/Share
|
|
Feb 14
2024
|
Daniel R Chard Chairman & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
16,486
+20.58%
|
-
|
|
Nov 07
2023
|
Scott Schlackman Director |
BUY
Open market or private purchase
|
Direct |
52
+0.49%
|
$3,536
$68.89 P/Share
|
|
Nov 07
2023
|
Michael A. Hoer Director |
BUY
Open market or private purchase
|
Direct |
49
+0.58%
|
$3,332
$68.89 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 94.9K shares |
|---|---|
| Exercise of conversion of derivative security | 1.3K shares |
| Payment of exercise price or tax liability | 4.17K shares |
|---|---|
| Open market or private sale | 4.05K shares |